Drug Trial Radar · NCT04924608
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
145
Actual
Start
Nov 19, 2021
Primary completion
Aug 5, 2024
Study completion Feb 15, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.
Conditions
- Neurofibromatosis 1
- Plexiform Neurofibroma (PN)
Interventions
SelumetinibDrug
Selumetinib oral capsules (10 mg and 25 mg)
PlaceboOther
Placebo oral capsules for Selumetinib masking (10 mg and 25 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Partial and Complete Response Rate (ORR) by End of Cycle 16 Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) in Participants With NF1 Who Have Symptomatic, Inoperable PN.Time frame: From first dose up until progression (if it occurs prior to the end of Cycle 16), or the last evaluable assessment up to and including the end of Cycle 16, excluding MRI during prolonged study intervention interruption (defined as interruption >= 28 days)
Locations
34 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Gainesville, Florida
Research Site
Rockville, Maryland
Research Site
St Louis, Missouri
Research Site
Commack, New York
Research Site
Melbourne, Australia
Research Site
St Leonards, Australia
Research Site
Porto Alegre, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Guangzhou, China
Research Site
Shenyang, China
Research Site
Créteil, France
Research Site
Lyon, France
Research Site
Toulouse, France
Research Site
Hamburg, Germany
Research Site
Tübingen, Germany
Research Site
Würzburg, Germany
Research Site
Milan, Italy
Research Site
Naples, Italy
Research Site
Roma, Italy
Research Site
Minatoku, Japan
Research Site
Nagoya, Japan
Research Site
Shinjuku-ku, Japan
Research Site
Bydgoszcz, Poland
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Badalona, Spain
Research Site
Madrid, Spain
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.